Table 7.
Medication Use and Prevalence of CMB
| Medication | Model 1* | Model 2 † | Model 3 ‡ | |
|---|---|---|---|---|
| Any CMB | ||||
| Any antiplatelet | 1.07 (0.81–1.40) | 1.05 (0.79–1.40) | 1.00 (0.74–1.35) | |
| Any anticoagulant | 1.64 (1.04–2.59) | 1.44 (0.91–2.29) | 1.21 (0.75–1.97) | |
| Any statin | 1.21 (0.95–1.56) | 1.29 (0.98–1.70) | 1.23 (0.92–1.64) | |
| Lobar CMB | ||||
| Any antiplatelet | 1.24 (0.80–1.91) | 1.17 (0.75–1.82) | 1.04 (0.66–1.64) | |
| Any anticoagulant | 1.96 (1.14–3.36) | 1.65 (0.95–2.88) | 1.34 (0.76–2.35) | |
| Any statin | 1.27 (0.86–1.87) | 1.30 (0.86–1.97) | 1.16 (0.76–1.76) | |
| Subcortical CMB | ||||
| Any antiplatelet | 1.04 (0.78–1.38) | 1.07 (0.80–1.45) | 1.01 (0.74–1.38) | |
| Any anticoagulant | 1.51 (0.94–2.43) | 1.38 (0.85–2.24) | 1.23 (0.74–2.05) | |
| Any statin | 1.12 (0.85–1.46) | 1.19 (0.88–1.61) | 1.15 (0.84–1.57) | |
| Deep CMB | ||||
| Any antiplatelet | 0.69 (0.33–1.42) | 0.64 (0.29–1.42) | 0.56 (0.25–1.23) | |
| Any anticoagulant | 1.27 (0.43–3.76) | 1.14 (0.39–3.37) | 0.94 (0.31–2.85) | |
| Any statin | 0.78 (0.48–1.25) | 0.81 (0.49–1.33) | 0.79 (0.47–1.32) | |
Data are given as odds ratio (95% CI). Unadjusted and unadjusted odds ratios for CMB, lobar CMB, subcortical CMB, and deep CMB are given as a function of any exposure to each medication of interest during the study period. CMB indicates cerebral microbleed.
*
Unadjusted model.
†
Model adjusted for propensity score quintile.
‡
Model adjusted for propensity score quintile, apolipoprotein E genotype, white matter hyperintensity volume, cognitive status, and any concomitant use of the other 2 medication types from visit 2 to visit 5.